

Product datasheet for TL320063V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Fucose mutarotase (FUOM) Human shRNA Lentiviral Particle (Locus ID 282969)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Fucose mutarotase (FUOM) Human shRNA Lentiviral Particle (Locus ID 282969)

Locus ID: 282969

Synonyms: C10orf125; FucM; FUCU

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: C10orf125 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001098483, NM 001301827, NM 001301828, NM 198472, NM 001098483.1,

NM 001098483.2, NM 198472.1, NM 198472.2, NM 001301828.1, NM 001301827.1, BC129819, BC129818, BM009909, NM 001301827.2, NM 001098483.3, NM 198472.3,

NM 001301828.2

UniProt ID: A2VDF0

Summary: Involved in the interconversion between alpha- and beta-L-fucoses. L-Fucose (6-deoxy-L-

galactose) exists as alpha-L-fucose (29.5%) and beta-L-fucose (70.5%), the beta-form is metabolized through the salvage pathway. GDP-L-fucose formed either by the de novo or salvage pathways is transported into the endoplasmic reticulum, where it serves as a substrate for N- and O-glycosylations by fucosyltransferases. Fucosylated structures

expressed on cell surfaces or secreted in biological fluids are believed to play a critical role in

cell-cell adhesion and recognition processes.[UniProtKB/Swiss-Prot Function]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).